ArticleEpidemiology and infection2026
Incidence of parvovirus B19 among Hungarian blood donor population during COVID-19 restrictions and the subsequent B19 epidemic of 2024.
Article in Epidemiology and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nationwide screening for parvovirus B19 among blood donors in Hungary has been conducted since 2019. Although B19 is primarily transmitted via the respiratory route, transfusion-related transmission also occurs. This study investigated the impact of COVID-19-related restrictions on B19 incidence. Between January 1 2019 and December 31 2024, a total of 2,043,119 blood donations were screened for B19 DNA using PCR, and the study period was divided into six epidemiological phases.During the pre-restriction period (Phase I), B19 incidence was relatively low (0.87/10,000 donations). Following the introduction of COVID-19 restrictions (Phase II), highly viremic donations were not detected. Incidence gradually returned in Phase III (0.22/10000) and increased in Phase IV (1.96/10000), suggesting a minor outbreak. A marked surge in December 2023 (23.03/10000) initiated a nationwide epidemic, peaking in March-April 2024 (46.01/10000), before declining by August (Phase VI; 0.54/10000).COVID-19 restrictions substantially reduced B19 transmission and may have led to increased population susceptibility. This likely contributed to the unusually intense B19 epidemic observed in 2024, which was considerably more severe than contemporaneous outbreaks reported in other countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.